Genmab — Juni 2025
-
Genmab har lovende resultater med kræftmiddel i lymfekræftform https://proinvestor.com/investornyt/1329375/genmab-har-lovende-resultater-med-kraeftmiddel-i-lymfekraeftform
-
Transactions in Connection with Share Buy-back Program https://proinvestor.com/investornyt/1329527/transactions-in-connection-with-share-buy-back-program
-
EHA 2025: Genmab and AbbVie’s Epkinly outpaces BiTE rivals in r/r DLBCL trial https://finance.yahoo.com/news/eha-2025-genmab-abbvie-epkinly-134631049.html
-
Hej wisuwa...Du kan evt starte med at læse chathistorikken.
https://proinvestor.com/chathistory/-25/genmab -
Jyske Bank: Genmab – Positivt nyt fra Epcoritamab https://proinvestor.com/investornyt/1329914/jyske-bank-genmab-positivt-nyt-fra-epcoritamab
-
España lidera un estudio pionero con epcoritamab para mejorar el abordaje del linfoma B de células grandes https://www.immedicohospitalario.es/noticia/51673/espana-lidera-un-estudio-pionero-con-epcoritamab-para-mejorar-el-abor.html REPIFIR = Response-adaptive to Epcoritamab In FIrst Relapse
-
Presentations & posters for EHA 2025 via https://www.genmabmedicalaffairs.com/congress?filv1=5
-
EHA 2025 – J&J claims an extramedullary edge
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy. https://www.oncologypipeline.com/apexonco/eha-2025-jj-claims-extramedullary-edge -
Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant https://www.ajmc.com/view/epcoritamab-plus-chemoimmunotherapy-yields-87-response-rate-in-r-r-dlbcl-65-proceed-to-transplant
-
EHA 2025 | How effective is epcoritamab + R-ICE in patients with R/R DLBCL who are ASCT eligible? https://www.youtube.com/watch?v=bCdPlWOjJ1M
-
RITUXIMAB AND EPCORITAMAB AS FIRST-LINE THERAPY FOR PATIENTS WITH HIGH-TUMOR BURDEN FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIAL https://onlinelibrary.wiley.com/doi/10.1002/hon.70094_227 -from the
18th International Conference on Malignant Lymphoma https://onlinelibrary.wiley.com/toc/10991069/2025/43/S3
-
Hemab Therapeutics
@Hemab_TxICYMI: Last week we announced the International Non-Proprietary Name (INN) sutacimig for HMB-001 — marking the first-ever INN for a treatment designated for Glanzmann thrombasthenia.https://x.com/Hemab_Tx/status/1935293889662898321
-
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Bleeding Disorder Programs at the ISTH 2025 Congress - HealthCap
Sutacimig (formerly HMB-001) continues to demonstrate promising interim safety, PK, and efficacy Phase 2 results in Glanzmann thrombasthenia and is granted its International Non-Proprietary Name designation by WHO HMB-002 shows promise in Von Willebrand disease with initial proof of mechanism clinical data from patients in ongoing VELORA Pioneer study, supported by comprehensive non-clinical package including […]
HealthCap (www.healthcap.eu)
-
Interim results show HMB-001 significantly reduces frequency of bleeding events with a favorable safety profile, supporting its potential as a novel prophylactic treatment for GT. HMB-001’s subcutaneous dosing offers a proactive alternative to reactive GT care, addressing a critical unmet need.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind